Corrigendum to “Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes” [The Journal of Prevention of Alzheimer's Disease (2026) 100507]
Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]
Authors
- Amanda Goodwin (ORCID: https://orcid.org/0000-0002-1488-6549)
- Michio Kanekiyo
- Mark Hodgkinson
- Shobha Dhadda (ORCID: https://orcid.org/0000-0002-7290-7168)
- Lutz Froelich (ORCID: https://orcid.org/0000-0003-1494-0813)
- Sarah J. Trafford
- Christopher Kipps (ORCID: https://orcid.org/0000-0002-5205-9712)
- María Martín (ORCID: https://orcid.org/0000-0001-5757-5938)
- Lynn D. Kramer
- Richard Perry
- Marco Bozzali
- Steven Hersch
- Giancarlo Logroscino
- Michael Irizarry
Institutions
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University Hospital Southampton NHS Foundation Trust (GB)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Central Institute of Mental Health (DE)
- Eisai (United Kingdom) (GB)
- Eisai (United States) (US)
- Imperial College London (GB)
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2026-03-14
- DOI
- https://doi.org/10.1016/j.tjpad.2026.100527
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00